6533b7d0fe1ef96bd125b79e

RESEARCH PRODUCT

CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease

Fabrizio CantiniPiercarlo Sarzi-puttiniGiuseppe PaolazziRenato La CorteCarlo SalvaraniBruno CasaliFabiola AtzeniGiovanni TrioloEnrico FarnettiDavide NicoliNicolò PipitoneFabrizio SalviDavide FilippiniLuigi BoiardiIgnazio Olivieri

subject

AdultMalemedicine.medical_specialtyHeterozygoteReceptors CCR5Behcet's disease CCR5 polymorphismBehcet's diseaseGastroenterologyRheumatologyGeneticGene FrequencyInternal medicineGenotypeReceptorsMedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismAllele frequencyPolymorphism Geneticbusiness.industryBehcet SyndromeHomozygoteCase-control studyOdds ratiomedicine.diseaseBeḩet's disease; CC chemokine receptor 5 Δ32 olymorphism; Chemokines; Disease manifestations; Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5; Rheumatology; Pharmacology (medical)Adult; Behcet Syndrome; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-B Antigens; Heterozygote; Homozygote; Humans; Italy; Male; Polymorphism Genetic; Receptors CCR5ItalyHLA-B AntigensCase-Control StudiesImmunologyCohortFemalebusinessCC chemokine receptorsCCR5

description

OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behcet's disease (BD) in a cohort of Italian patients. METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations. RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls (P = 0.02). The CCR5Δ32 allele was more common in BD patients than in controls [P = 0.02, odds ratio (OR) 2.28 (95% CI 1.1, 4.8)]. Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more common in BD patients than in controls [P = 0.02, OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing patients according to gender, the association between CCR5Δ32 polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies of clinical manifestations were compared between CC5RΔ32 allele carriers and non-carriers. CONCLUSION: CCR5Δ32 polymorphism is associated with an increased susceptibility to develop BD. Chemokines may have a role in the pathophysiology of BD.

10.1093/rheumatology/kes238http://hdl.handle.net/11570/3125307